NCT02913794已完成不适用
A Single-center Cross-sectional Study to Evaluate the Effectiveness of Antihypertensive Treatment Including Fimasartan and the Dyslipidemia Treatment Including Rosuvastatin and to Assess the Association Between the Two Treatments
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 541
- 试验地点
- 1
- 主要终点
- Co-relation between blood pressure and dyslipidemia
研究概览
简要总结
Fimasartan and Rosuvastatin for hypertension and dyslipidemia control
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Hypertension patients who are taking an anti-hypertensive agent, including Fimasartan at least 12 weeks or more.
- •Dyslipidemia patients who are taking dyslipidemia drug, including Rosuvastatin at least 12 weeks or more
- •Patients who has blood pressure and lipid levels (Total cholesterol, LDL-C, HDL-C, non-HDL-C, * TG) checks 2 weeks before registration
排除标准
- •Patients being hospitalized
- •Patients who stop taking Fimasartan or Rosuvastatin within 12 weeks 14 or more consecutive days
- •Patients who have more than 400mg/dl triglyceride(TG) at the registration time
结局指标
主要结局
Co-relation between blood pressure and dyslipidemia
时间窗: 12 weeks
Check the blood pressure and dyslipidemia control rates, also check the correlation between these two disease
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapyEssential HypertensionNCT01258673Boryung Pharmaceutical Co., Ltd263
Unknown
3 期
Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With HyperlipidemiaHyperlipidemiaHypertensionNCT02087540IlDong Pharmaceutical Co Ltd310
已完成
3 期
Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension PatientsHypertensionNCT00922480Boryung Pharmaceutical Co., Ltd506
已完成
不适用
Fimasartan Blood Pressure Lowering After Acute StrokeIschemic StrokeHypertensionTransient Ischemic AttackNCT03231293Boryung Pharmaceutical Co., Ltd1,035
已完成
4 期
Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial DysfunctionHypertensionDyslipidemiaNCT00171327Novartis213